IR@PKUHSC  > 北京大学第二临床医学院
学科主题临床医学
Weight-neutral effect of once-daily insulin detemir in Chinese type 2 diabetes patients: Subgroup analysis of the SOLVE study
Pan, Changyu1; Han, Ping4; Ji, Linong2; Ji, Qiuhe5; Lu, Juming1; Lin, Jing3; Liu, Jie6; Su, Benli7; Shi, Jingmei8; Wang, Penghua9
关键词body mass index body weight insulin detemir type 2 diabetes mellitus
刊名JOURNAL OF DIABETES
2015-03-01
DOI10.1111/1753-0407.12179
7期:2页:222-230
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Endocrinology & Metabolism
研究领域[WOS]Endocrinology & Metabolism
关键词[WOS]IMPROVES GLYCEMIC CONTROL ; NPH INSULIN ; NAIVE PATIENTS ; BODY-WEIGHT ; FOOD-INTAKE ; THERAPY ; GAIN ; MELLITUS ; OVERWEIGHT ; GLARGINE
英文摘要

BackgroundThe present subanalysis of the Study of Once Daily Levemir (SOLVE) study was to evaluate the safety and efficacy of once-daily insulin detemir as add-on to oral antidiabetic drugs (OADs) in Chinese type 2 diabetes patients according to body mass index in a real-life setting.

MethodsIn all, 3272 eligible patients who were treated with diet, exercise, and one or more OAD were prescribed once-daily insulin detemir by their physician according to routine clinical practice and were followed-up for 24 weeks. The incidence of serious adverse reactions (SADRs), including major hypoglycemia, was the primary endpoint. Subanalyses were performed on patients in the following BMI groups: normal weight (BMI<25kg/m(2)); overweight (25BMI<30kg/m(2)); and obese (BMI30kg/m(2)).

ResultsNo SADRs were reported during the study. Significant improvements in glycemic levels were observed in all subgroups. For normal weight, overweight, and obese patients, the mean change in HbA1c (%/[mmol/mol]) was -1.26/-14, -1.09/-12, and -1.06/-12, respectively. The mean change in fasting plasma glucose in normal weight, overweight, and obese patients was -2.77, -2.57, and -2.71mmol/L, respectively. Slight weight gain (0.25kg), slight weight loss (-0.36kg), and weight loss (-1.32kg) were observed in the normal weight, overweight, and obese patients, respectively (P<0.001). Linear regression analysis revealed a negative relationship between weight change and baseline BMI (slope=-0.16; P<0.001).

ConclusionsOnce-daily insulin detemir as add-on to OADs in Chinese patients with type 2 diabetes showed effective glycemic control and a low risk of hypoglycemia. Weight-neutral effects were observed in different BMI subgroups.

语种英语
WOS记录号WOS:000349127200013
资助机构Novo Nordisk
引用统计
被引频次:2[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/63660
专题北京大学第二临床医学院
作者单位1.Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China
2.Beijing Huaxin Hosp, Beijing, Peoples R China
3.4th Mil Med Univ, Xijing Hosp, Xian, Peoples R China
4.Shanxi Prov Peoples Hosp, Taiyuan, Peoples R China
5.Dalian Med Univ, Affiliated Hosp 2, Dalian, Peoples R China
6.Yuncheng Tongde Hosp, Yuncheng, Peoples R China
7.Tianjin Med Univ, Metab Dis Hosp, Tianjin, Peoples R China
8.Chinese Peoples Liberat Army Gen Hosp, Beijing 100853, Peoples R China
9.China Med Univ, Shengjing Hosp, Shenyang 110001, Peoples R China
推荐引用方式
GB/T 7714
Pan, Changyu,Han, Ping,Ji, Linong,et al. Weight-neutral effect of once-daily insulin detemir in Chinese type 2 diabetes patients: Subgroup analysis of the SOLVE study[J]. JOURNAL OF DIABETES,2015,7(2):222-230.
APA Pan, Changyu.,Han, Ping.,Ji, Linong.,Ji, Qiuhe.,Lu, Juming.,...&Wang, Penghua.(2015).Weight-neutral effect of once-daily insulin detemir in Chinese type 2 diabetes patients: Subgroup analysis of the SOLVE study.JOURNAL OF DIABETES,7(2),222-230.
MLA Pan, Changyu,et al."Weight-neutral effect of once-daily insulin detemir in Chinese type 2 diabetes patients: Subgroup analysis of the SOLVE study".JOURNAL OF DIABETES 7.2(2015):222-230.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Pan, Changyu]的文章
[Han, Ping]的文章
[Ji, Linong]的文章
百度学术
百度学术中相似的文章
[Pan, Changyu]的文章
[Han, Ping]的文章
[Ji, Linong]的文章
必应学术
必应学术中相似的文章
[Pan, Changyu]的文章
[Han, Ping]的文章
[Ji, Linong]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。